Catégorie : Essais Cliniques

Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use, Paulo Fleury-Teixeira et al., 2019

Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, October 2019, Volume 10, Article 1145 doi : 10.3389/fneur.2019.01145   Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]

Lire la suite

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial, Berzenn Urbi et al., 2019,

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease progression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial Berzenn Urbi, Simon Broadley, Richard Bedlack, Ethan Russo, Arman Sabet British Medical Journal Open, 2019, 9, e029449. doi : 10.1136/bmjopen-2019-029449   Abstract Introduction : Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3–5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy [...]

Lire la suite

Ayahuasca : Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness, Jonathan Hamill et al., 2019

Ayahuasca : Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness Jonathan Hamill, Jaime Hallak, Serdar M. Dursun and Glen Baker Current Neuropharmacology, 2019, 17, 108-128. Doi : 10.2174/1570159X16666180125095902   Abstract Background : Ayahuasca, a traditional Amazonian decoction with psychoactive properties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) andleaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communication, magical experiences, healing, and religious rituals across several South American countries, ayahuasca has been incorporated into folk medicine and spiritual healing, and several Brazilian churches use [...]

Lire la suite

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users : A Pragmatic Open-Label Clinical Trial, Nadia Solowij et al., 2018

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users : A Pragmatic Open-Label Clinical Trial Nadia Solowij, Samantha J. Broyd, Camilla Beale, Julie-Anne Prick, Lisa-marie Greenwood, Hendrika van Hell, Chao Suo, Peter Galettis, Nagesh Pai, Shanlin Fu, Rodney J. Croft, Jennifer H. Martin, and Murat Yücel Cannabis and Cannabinoid Research, 2018, 3, 1,21-35 Doi : 10.1089/can.2017.0043   Abstract Introduction : Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While D9-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to [...]

Lire la suite

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial, Richard J. Zeifman et al., 2019

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime Hallak, Emerson Arcoverde, João Paulo Maia-Oliveira, Draulio B. Araujo Frontiers in Pharmacology, 2019, Volume 10, Article 1325, 1-10. doi : 10.3389/fphar.2019.01325   Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in [...]

Lire la suite

Psilocybin-assisted therapy for depression : How do we advance the field ?, Sally E Meikle et al., 2019

Psilocybin-assisted therapy for depression : How do we advance the field ? Sally E Meikle, Paul Liknaitzky, Susan L Rossell, Margaret Ross, Nigel Strauss, Neil Thomas, Greg Murray, Martin Williams, David J Castle Australian & New Zealand Journal of Psychiatry, 2019, 1–7 Doi : 10.1177/0004867419888575   Abstract In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use [...]

Lire la suite

CBD Isolates Vs. Full-Spectrum CBD, Martin A. LEE, projectCBD.org, 2015

CBD Isolates Vs. Full-Spectrum CBD Martin A. Lee On February 22, 2015 https://www.projectcbd.org/science/cbd-isolates-vs-full-spectrum-cbd A groundbreaking study has documented the superior therapeutic properties of whole plant CBD-rich cannabis extract as compared to single-molecule CBD.   A groundbreaking study from Israel has documented the superior therapeutic properties of whole plant CBD-rich cannabis extract as compared to single-molecule cannabidiol (CBD). Published in the journal Pharmacology & Pharmacy (Feb. 2015), the article directly challenges one of the sacred cows of Big Pharma and the medical-industrial complex—the notion that “crude” botanical preparations are inherently low grade and less effective than pure, single-molecule compounds. Entitled “Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis [...]

Lire la suite

CBD User’s Guide, ProjectCBD.org, 2019

CBD User's Guide Project CBD On March 13, 2018 (Updated on March 25, 2019) https://www.projectcbd.org/how-to/cbd-users-guide   Project CBD has created a beginner’s guide for cannabidiol & cannabis therapeutics to address key questions of CBD users. A Beginner’s Guide to CBD & Cannabis Therapeutics   In 2009, a handful of CBD-rich cannabis strains were discovered serendipitously in Northern California, America’s cannabis breadbasket, where certified patients could access medical marijuana legally. Thus began a great laboratory experiment in democracy involving CBD-rich cannabis therapeutics. The advent of whole plant CBD-rich oil as a grassroots therapeutic option has changed the national conversation about cannabis. It’s no longer a question of whether [...]

Lire la suite

Cannabinoids in the treatment of epilepsy – an updated review, Marcin Kopka, 2019

Cannabinoids in the treatment of epilepsy – an updated review Marcin Kopka Journal of Epileptology, 2019, 27, Doi : 10.2478/joepi-2019-0004   SUMMARY Introduction : It is estimated that 30% of people with epilepsy continue to have seizures despite treatment. The approval of many new antiseizure drugs during the past two decades has not substantially reduced the proportion of patients with medically refractory disease. Patients need new treatments. Many families choose to try alternative therapy options. An abundance of preclinical evidence and anecdotal human data support the use of cannabinoids in the treatment of epilepsy. Aim : The present review paper aims to present the current state of [...]

Lire la suite

Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone, Roberto Frau et al., 2019

Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone Roberto Frau, Vivien Miczán, Francesco Traccis, Sonia Aroni, Csaba I. Pongor, Pierluigi Saba, Valeria Serra, Claudia Sagheddu, Silvia Fanni, Mauro Congiu, Paola Devoto, Joseph F. Cheer, István Katona and Miriam Melis Nature Neuroscience,  December 2019, VOL 22, 1975–1985 www.nature.com/natureneuroscience1975 Content courtesy of Springer Nature, terms of use apply. Rights reserved Doi : 10.1038/s41593-019-0512-2 The increased legal availability of cannabis has led to a common misconception that it is a safe natural remedy for, among others, pregnancy-related ailments such as morning sickness. Emerging clinical evidence, however, indicates that prenatal cannabis exposure (PCE) predisposes offspring to various neuropsychiatric [...]

Lire la suite